Tag: Hep C reinfection

CATIE’s HepCInfo Update 6.12

New and Noteworthy Daclatasvir receives breakthrough therapy status from the FDA The U.S. Food and Drug Administration (FDA) has granted a breakthrough therapy designation for daclatasvir when used with the already approved medication sofosbuvir (Sovaldi) in people with advanced liver damage. When a medication is designated as a breakthrough therapy the FDA speeds up its… Read more »

CATIE HepCinfo Update

New and Noteworthy 15 year study shows benefits of harm reduction programs in Vancouver Harm reduction programs in Vancouver have reduced drug use and needle sharing, leading to fewer HIV and Hep C infections and increased access to addiction treatment, concludes the report “Drug Situation in Vancouver”. The report, published by the Urban Health Initiative… Read more »